## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App	licant	(s):	Jacob Waugh et al.				
Serial No.:		.:	10/591,485	Group Art Unit:	1656		
Filed:			November 7, 2007	Examiner: Confirmation No:	Samuel W. Liu		
For:			Multi-Component Biological Tran		1919		
P.O.	Box	1450	or Patents 22313-1450				
			INFORMATION DISCL	OSURE STATEME	<u>NT</u>		
Sir:							
		Т	his Information Disclosure Staten	nent is filed in accord	ance with 37 C.F.R.		
§§1	56, 1.	97 and	11.98. The items listed on Form F	TO-1449, a copy of	which is enclosed, are		
			o assist the Patent and Trademark				
			respectfully requested to fully con				
	teach				•		
1.		For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:					
2.		For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.					
<b>3</b> , <b>3</b>		Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed					
		~~~~					
ł. [		No fee since i	e is due under 37 C.F.R. §1.17(p) to it is being filed in compliance with	for this Information E i:	Disclosure Statement		
			37 C.F.R. §1.97(b)(1), within the application other than a CPA; or	ee months of the filir	ig date of a national		
			37 C.F.R. §1.97(b)(2), within the national stage as set forth in §1.4	ee months of the date 91 in an international	of entry into the application; or		

		LJ	merits; or	
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.	
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specifi in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.		
6. 🛚		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):		
			A check in the amount of \$180.00 is enclosed in payment of the fee.	
		$\boxtimes$	Charge the fee to Deposit Account No. 50-3732, Order No. 13720-105074.	
7.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:		
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and	
			the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.	
8.		This I	nformation Disclosure Statement is being filed in compliance with:	
		a. 🔲	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
		ъ. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
		c	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.	
9.			by certify that each item of information contained in this Information Disclosure	

	counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.				
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
10.	This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.				
11.	A check in the amount of \$\\$ is enclosed in payment of the fees due under 37 C.F.R. \\$\\$1.17(h) and 1.17(p).				
	Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No				
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105074.				
Dated: !	Respectfully submitted, KING & SPALDING LLP May 20, 2011  By:				
	Joseph D. Eng, Jr. Reg. No. 54,084				
<u>Corresp</u>	ondence Address:				
King &	Spalding LLP				

1185 Avenue of the Americas New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile